Human relevance of NRAS/BRAF mouse melanoma models

被引:13
|
作者
Conde-Perez, Alejandro [1 ,2 ,3 ]
Larue, Lionel [1 ,2 ,3 ]
机构
[1] Inst Curie, F-91405 Orsay, France
[2] CNRS, UMR3347, F-75700 Paris, France
[3] INSERM, U1021, F-75654 Paris 13, France
关键词
PTEN; beta-Catenin; p16(INK4A); Melanomagenesis; Initiation; Progression; BETA-CATENIN; CUTANEOUS MELANOMA; GENERAL STRATEGY; PTEN; BRAF; MUTATIONS; EXPRESSION; SENESCENCE; PATHWAYS; SKIN;
D O I
10.1016/j.ejcb.2013.10.010
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Melanoma is a major problem for many individuals worldwide. Although no effective treatment is available, promising new strategies are being developed. A better understanding of the inner workings of the disease would undoubtedly lead to improved treatments. Mouse melanoma models have been used to elucidate many key regulatory pathways involved in melanoma initiation and progression, and models with mutations in the oncogenes RAF and RAS have been particularly informative. Here, we summarize and evaluate the human relevance of various RAF and RAS mouse melanoma models and their contribution to our understanding of melanoma. (C) 2013 Elsevier GmbH. All rights reserved.
引用
收藏
页码:82 / 86
页数:5
相关论文
共 50 条
  • [1] UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma
    Bowman, Robert L.
    Hennessey, Rebecca C.
    Weiss, Tirzah J.
    Tallman, David A.
    Crawford, Emma R.
    Murphy, Brandon M.
    Webb, Amy
    Zhang, Souhui
    La Perle, Krista Md
    Burd, Craig J.
    Levine, Ross L.
    Shain, A. Hunter
    Burd, Christin E.
    LIFE SCIENCE ALLIANCE, 2021, 4 (09)
  • [2] Preclinical therapeutics in genetically engineered mouse models of inducible NRAS and BRAF mutant melanoma
    Kwong, Lawrence N.
    Jiang, Shan
    Liu, Huiyun
    Chin, Lynda
    CANCER RESEARCH, 2011, 71
  • [3] Mouse models of melanoma driven by oncogenic NRAS
    Pedersen, Malin
    Viros, Amaya
    Marais, Richard
    MOLECULAR CANCER RESEARCH, 2014, 12
  • [4] Specific roles for BRAF and CRAF in NRAS-induced mouse melanoma
    Dorard, C.
    Larcher, M.
    Pouponnot, C.
    Beermann, F.
    Baccarini, M.
    Larue, L.
    Eychene, A.
    Druillennec, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S857 - S857
  • [5] Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
    Ellerhorst, Julie A.
    Greene, Victoria R.
    Ekmekcioglu, Suhendan
    Warneke, Carla L.
    Johnson, Marcella M.
    Cooke, Carolyn P.
    Wang, Li-E
    Prieto, Victor G.
    Gershenwald, Jeffrey E.
    Wei, Qingyi
    Grimm, Elizabeth A.
    CLINICAL CANCER RESEARCH, 2011, 17 (02) : 229 - 235
  • [6] BRAF, NRAS, HRAS genes profile in human melanoma cell lines
    Czajkowski, Rafal
    Placek, Waldemar
    Tadrowski, Tadeusz
    Pokrywczynska, Marta
    Zegarska, Barbara
    Drewa, Tomasz
    PRZEGLAD DERMATOLOGICZNY, 2009, 96 (04): : 265 - 270
  • [7] Establishment of in vivo and in vitro mouse models relevant for human cutaneous melanoma mutated for NRAS
    Petit, V.
    Delmas, V.
    Beermann, F.
    Larue, L.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S288 - S288
  • [8] Absence of BRAF and NRAS mutations in uveal melanoma
    Cruz, F
    Rubin, BP
    Wilson, D
    Town, A
    Schroeder, A
    Haley, A
    Bainbridge, T
    Heinrich, MC
    Corless, CL
    CANCER RESEARCH, 2003, 63 (18) : 5761 - 5766
  • [9] BRAF and NRAS mutations in melanoma and melanocytic nevi
    Poynter, Jenny N.
    Elder, James T.
    Fullen, Douglas R.
    Nair, Rajan P.
    Soengas, Maria S.
    Johnson, Timothy M.
    Redman, Bruce
    Thomas, Nancy E.
    Gruber, Stephen B.
    MELANOMA RESEARCH, 2006, 16 (04) : 267 - 273
  • [10] Atypical BRAF and NRAS Mutations in Mucosal Melanoma
    Dumaz, Nicolas
    Jouenne, Fanelie
    Delyon, Julie
    Mourah, Samia
    Bensussan, Armand
    Lebbe, Celeste
    CANCERS, 2019, 11 (08)